Abstract
<h3>Objective:</h3> N/A <h3>Background:</h3> There is currently limited literature on the localization value of ictal SPECT tracer injection during patient-reported typical focal aware seizures (auras) that lack electrographic changes. One study reported that ictal SPECT studies in isolated auras lack reliability, with concordant localization with the seizure onset zone obtained in 5%, and lateralization in 35% of cases. In another study, localizing information of self-injection of ictal SPECT was better in three patients and obviated the need for intracranial monitoring in one patient. We present a study in which tracer injection was administered for patient-reported typical focal aware seizures, where the subsequent analysis of ictal and interictal SPECT helped inform further management. <h3>Design/Methods:</h3> We performed a retrospective review of cases who underwent ictal SPECT between 2020 to 2022 at University of Kentucky hospital. Cases with radiotracer injection during patient-reported auras lacking electrographic changes were identified. Timing of injection from onset of reported aura, hyperperfusion changes on ictal SPECT, and the outcome of imaging on further management of refractory epilepsy were noted. <h3>Results:</h3> 20 patients underwent ictal SPECT, of which 7 met our inclusion criteria. None of the 7 cases had electrographic correlate with aura on scalp EEG. Time of tracer injection ranged from 1–17 seconds following onset of aura. The ictal SPECT changes correctly localized the seizure onset zone in five patients. This was followed by intracranial monitoring and subsequent temporal lobectomy in three patients, interventricular ablation of epileptogenic focus in one patient, and Responsive Neurostimulation implant in one patient. One patient was managed medically, and one is ongoing pre-surgical evaluation. <h3>Conclusions:</h3> Ictal SPECT with radiotracer injection during typical focal aware seizures (patient reported auras) without ictal electrographic changes is helpful in the localization of the seizure onset zone. Additional studies with larger sample size and outcome information are needed to assess accuracy of localization. <b>Disclosure:</b> Dr. Pervin has nothing to disclose. Dr. Khan has received personal compensation for serving as an employee of University of Kentucky. Dr. Clay has nothing to disclose. Riham El Khouli has nothing to disclose. Dr. Mirza has nothing to disclose. Dr. Mathias has received research support from My Epilepsy Society Non Profit Organization.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.